Skip to main content
. 2021 Apr 26;139(3):241–250. doi: 10.1590/1516-3180.2020.0349.R1.28012021

Table 1. Demographic, clinical and pathological data and oncological outcomes of the patients.

Parameters

  • Group I

  • (n = 39)

  • Group II

  • (n = 41)

  • Total

  • (n = 80)

 P-value

  • Median age (25th 75th percentile)

  • minimum-maximum

  • 68.00 (64.00-69.00)

  • 56-74

  • 66.00 (63.00-69.50)

  • 57-74

  • 66.00 (63.00-69.00)

  • 56-74

 0.367§
Median BMI (25th 75th percentile) 25.20 (23.10-27.80) 24.50 (21.95-27.10) 24.65 (22.35-27.57) 0.174§
Median preoperative PSA level (25th 75th percentile) 7.44 (5.19-9.60) 8.95 (6.38-11.00) 8.00 (6.03-10.34) 0.115§
Biopsy Gleason grade (n, %)

  • -6

  • -7

  • -8

  • -9

  • -10

  • 30 (76.9)

  • 5 (12.9)

  • 2 (5.1)

  • 2 (5.1)

  • 0 (0.0)

  • 26 (63.5)

  • 6 (14.6)

  • 6 (14.6)

  • 2 (4.9)

  • 1 (2.4)

  • 56 (70.0)

  • 11 (13.7)

  • 8 (10.0)

  • 4 (5.0)

  • 1 (1.3)

 0.504‡
Preoperative clinical T stage (n, %)

  • -T1c

  • -T2a

  • -T2b

  • -T2c

  • -T3a

  • 24 (61.5)

  • 7 (17.9)

  • 1 (2.6)

  • 6 (15.4)

  • 1 (2.6)

  • 31 (75.6)

  • 4 (9.8)

  • 3 (7.3)

  • 2 (4.9)

  • 1 (2.4)

  • 55 (68.7)

  • 11 (13.8)

  • 4 (5.0)

  • 8 (10.0)

  • 2 (2.5)

 0.324‡
Post-prostatectomy Gleason grade (n, %)

  • -6

  • -7

  • -8

  • -9

  • -10

  • 20 (51.3)

  • 10 (25.6)

  • 5 (12.8)

  • 4 (10.3)

  • 0 (0.0)

  • 23 (56.1)

  • 7 (17.1)

  • 8 (19.5)

  • 0 (0.0)

  • 3 (7.3)

  • 43 (53.8)

  • 17 (21.3)

  • 13 (16.3)

  • 4 (5.0)

  • 3 (3.8)

 0.894‡
Post-prostatectomy pathological T stage (n, %)

  • -T2a

  • -T2b

  • -T2c

  • -T3a

  • -T3b

  • 8 (20.5)

  • 5 (12.8)

  • 13 (33.4)

  • 6 (15.4)

  • 7 (17.9)

  • 18 (43.9)

  • 4 (9.8)

  • 8 (19.5)

  • 5 (12.2)

  • 6 (14.6)

  • 26 (32.5)

  • 9 (11.1)

  • 21 (26.3)

  • 11 (13.8)

  • 13 (16.3)

 0.261‡
Surgical margin positivity (n, %)

  • -Yes

  • -No

  • 4 (10.3)

  • 35 (89.7)

  • 7 (17.1)

  • 34 (82.9)

  • 11 (13.8)

  • 69 (86.3)

 0.376‡
Post-prostatectomy PSA recurrence (n, %)

  • -Yes

  • -No

  • 12 (30.8)

  • 27 (69.2)

  • 14 (34.1)

  • 27 (65.9)

  • 26 (32.5)

  • 54 (67.5)

 0.747‡
Median pre-prostatectomy ASA score (25th 75th percentile) 2.00 (2.00-3.00) 2.00 (1.50-3.00) 2.00 (2.00-3.00) 0.745§
Median pre-prostatectomy ACCI score (25th 75th percentile) 5.00 (4.00-6.00) 5.00 (5.00-6.00) 5.00 (4.00-6.00) 0.437§
Presence of preoperative hypertension (n, %)

  • -Present

  • -Absent

  • 21 (53.8)

  • 18 (46.2)

  • 18 (43.9)

  • 23 (56.1)

  • 39 (48.8)

  • 41 (51.2)

 0.374‡
Presence of preoperative diabetes mellitus (n, %)

  • -Present

  • -Absent

  • 17 (43.6)

  • 22 (56.4)

  • 16 (39.0)

  • 25 (61.0)

  • 33 (41.3)

  • 47 (58.8)

 0.678‡
Presence of smoking (n, %)

  • -Present

  • -Absent

  • 20 (51.3)

  • 19 (48.7)

  • 23 (56.1)

  • 18 (43.9)

  • 43 (53.8)

  • 37 (46.3)

 0.666‡
Intraoperative excessive blood loss (> 1000 ml) (n, %)

  • -Present

  • -Absent

  • 13 (33.3)

  • 26 (66.7)

  • 15 (36.6)

  • 26 (63.4)

  • 28 (35.0)

  • 52 (65.0)

 0.761‡
Prolonged leakage at the anastomotic site (> 100 ml in the drainage tube) (n, %)

  • -Present

  • -Absent

  • 9 (23.1)

  • 30 (76.9)

  • 12 (29.3)

  • 29 (70.7)

  • 21 (26.2)

  • 59 (73.8)

 0.529‡
Q max prior to operation for VUAS (ml/s) 8.03 ± 1.53 7.74 ± 1.09 7.88 ± 1.33 0.338†
Postvoid residual volume prior to operation for VUAS (ml) 92.97 ± 9.67 90.02 ± 10.04 91.46 ± 9.91 0.185†
Median time until occurrence of VUAS (months) (25th 75th percentile) 9.00 (6.00-12.00) 10.00 (7.00-12.00) 9.00 (7.00-12.00) 0.433§
Recurrence of VUAS (n, %)

  • -Present

  • -Absent

  • 8 (20.5)

  • 31 (79.5)

  • 9 (22.0)

  • 32 (78.0)

  • 17 (21.3)

  • 63 (78.7)

 0.875‡
Median time until the recurrence of VUAS (months) (25th 75th percentile) 7.00 (6.00-8.75) 9.00 (5.00-10.00) 8.00 (6.00-10.00) 0.373§

  • Median total number of occurrences of VUAS (25th 75th percentile)

  • minimum-maximum

  • 1.00 (1.00-2.00)

  • 1-3

  • 1.00 (1.00-2.00)

  • 1-3

  • 1.00 (1.00-2.00)

  • 1-3

 0.489§
Median VSS score (25th 75th percentile) 5 (4-6) 4 (3-6) 4 (4-6) 0.083§

  • Median total follow-up period (months) (25th 75th percentile)

  • minimum-maximum

  • 79.00 (23.00-84.00)

  • 12-105

  • 67.00 (62.00-78.00)

  • 18-99

  • 72.00 (57.75-82.75)

  • 12-105

 0.467§

ACCI = age-adjusted Charlson comorbidity index; ASA = American Society of Anesthesiologists; BMI = body mass index; PSA = prostate-specific antigen; VSS = Vancouver scar scale, VUAS = vesicourethral anastomotic stenosis.

Group I comprises patients who underwent dilatation using Amplatz renal dilators; Group II comprises patients who underwent endoscopic bladder neck incision and/or resection”

§Mann-Whitney U test; data are expressed as “median (25th percentile-75th percentile)”; ‡Chi-square test; data are expressed as “number (percent)”; †independent-sample t test; data are expressed as “mean ± standard deviation”;

P < 0.05 indicates statistical significance; however, there are no significant values in this table.